You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClonidine
Accession NumberDB00575  (APRD00174, DB07566)
TypeSmall Molecule
GroupsApproved
DescriptionClonidine, an imidazoline-derivative hypotensive agent is a centrally-acting α2-adrenergic agonist. It crosses the blood-brain barrier and acts in the hypothalamus to induce a decrease in blood pressure. It may also be administered as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone. Clonidine may be used for differential diagnosis of pheochromocytoma in hypertensive patients. Other uses for clonidine include prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD). Clonidine also exhibits some peripheral activity.
Structure
Thumb
Synonyms
2-[(2,6-Dichlorophenyl)imino]imidazoline
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
Chlofazoline
Clonidin
Clonidina
Clonidinum
External Identifiers
  • ST 155
  • ST 155-BS
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cataprestablet.1 mg/1oralBoehringer Ingelheim Pharmaceuticals Inc.1999-05-01Not applicableUs
Cataprespatch, extended release.2 mg/24htransdermalBoehringer Ingelheim Pharmaceuticals Inc.1985-10-01Not applicableUs
Cataprestablet.2 mg/1oralBoehringer Ingelheim Pharmaceuticals Inc.1999-05-01Not applicableUs
Cataprespatch, extended release.3 mg/24htransdermalBoehringer Ingelheim Pharmaceuticals Inc.1985-10-01Not applicableUs
Cataprestablet.3 mg/1oralBoehringer Ingelheim Pharmaceuticals Inc.1999-05-01Not applicableUs
Cataprespatch, extended release.1 mg/24htransdermalRebel Distributors Corp1985-10-01Not applicableUs
Cataprespatch, extended release.1 mg/24htransdermalBoehringer Ingelheim Pharmaceuticals Inc.1985-10-01Not applicableUs
Catapres Tab 0.1mgtablet0.1 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1973-12-31Not applicableCanada
Catapres Tab 0.2mgtablet0.2 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1974-12-312015-03-30Canada
Clonidinetablet0.2 mgoralSanis Health Inc2011-02-082012-08-03Canada
Clonidinetablet0.025 mgoralSanis Health Inc2011-02-082012-08-03Canada
Clonidinetablet0.1 mgoralSanis Health Inc2011-02-082012-08-03Canada
Clonidine 0.1tablet0.1 mgoralPro Doc Limitee1991-12-312014-07-24Canada
Clonidine HCl Tab 0.2mgtablet.2 mgoralPro Doc Limitee1991-12-312014-07-24Canada
Clonidine Hydrochloridetablet.3 mg/1oralState of Florida DOH Central Pharmacy2009-06-20Not applicableUs
Clonidine Hydrochloride Extended-releasetablet, extended release.1 mg/1oralConcordia Pharmaceuticals Inc.2010-12-09Not applicableUs
Dixarit Tab 0.025mgtablet0.025 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1981-12-31Not applicableCanada
Dom-clonidinetablet.1 mgoralDominion Pharmacal2003-05-22Not applicableCanada
Dom-clonidinetablet.2 mgoralDominion Pharmacal2003-05-22Not applicableCanada
Duracloninjection, solution.5 mg/mLepiduralMylan Institutional LLC1996-10-02Not applicableUs
Duracloninjection, solution.1 mg/mLepiduralMylan Institutional LLC1996-10-02Not applicableUs
Kapvaytablet, extended release.1 mg/1oralConcordia Pharmaceuticals Inc.2010-12-09Not applicableUs
Kapvaytablet, extended release.2 mg/1oralConcordia Pharmaceuticals Inc.2010-12-09Not applicableUs
Nexiclontablet, extended release.17 mg/1oralTris Pharma, Inc.2010-12-17Not applicableUs
Nexiclon XRfor suspension, extended release.09 mg/mLoralTris Pharma, Inc.2010-12-17Not applicableUs
Nexiclon XRtablet, extended release.26 mg/1oralTris Pharma, Inc.2010-12-17Not applicableUs
Ntp-clonidinetablet0.025 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-clonidinetablet0.1 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-clonidinetablet0.2 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-clonidine Tab 0.1mgtablet.1 mgoralNu Pharm Inc1992-12-312012-09-04Canada
Nu-clonidine Tab 0.2mgtablet.2 mgoralNu Pharm Inc1992-12-312012-09-04Canada
Teva-clonidinetablet0.025 mgoralTeva Canada Limited2008-06-26Not applicableCanada
Teva-clonidinetablet0.2 mgoralTeva Canada Limited1993-12-31Not applicableCanada
Teva-clonidinetablet0.1 mgoralTeva Canada Limited1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clonidinetablet0.025 mgoralApotex Inc2004-07-13Not applicableCanada
Apo-clonidine Tab 0.1mgtablet.1 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-clonidine Tab 0.2mgtablet.2 mgoralApotex Inc1990-12-31Not applicableCanada
Clonidinepatch.1 mg/dtransdermalPhysicians Total Care, Inc.2011-09-24Not applicableUs
Clonidineinjection, solution500 ug/mLepiduralX Gen Pharmaceuticals, Inc.2013-10-29Not applicableUs
Clonidinepatch.3 mg/dtransdermalMylan Pharmaceuticals Inc.2013-02-08Not applicableUs
Clonidinepatch, extended release.2 mg/24htransdermalLake Erie Medical DBA Quality Care Products LLC2010-08-25Not applicableUs
Clonidinepatch, extended release.2 mg/24htransdermalBarr Laboratories Inc.2010-08-25Not applicableUs
Clonidinepatch, extended release.3 mg/24htransdermalBarr Laboratories Inc.2010-08-25Not applicableUs
Clonidinepatch.2 mg/dtransdermalPhysicians Total Care, Inc.2010-12-14Not applicableUs
Clonidineinjection, solution500 ug/mLepiduralFresenius Kabi USA, LLC2011-07-08Not applicableUs
Clonidinepatch.1 mg/dtransdermalMylan Pharmaceuticals Inc.2013-02-08Not applicableUs
Clonidinepatch.3 mg/dtransdermalPhysicians Total Care, Inc.2011-05-10Not applicableUs
Clonidinetablet.1 mg/1oralSTAT Rx USA LLC1986-12-16Not applicableUs
Clonidinepatch, extended release.1 mg/24htransdermalBarr Laboratories Inc.2010-08-25Not applicableUs
Clonidinepatch.2 mg/dtransdermalLake Erie Medical DBA Quality Care Products LLC2013-02-08Not applicableUs
Clonidinepatch.2 mg/dtransdermalMylan Pharmaceuticals Inc.2013-02-08Not applicableUs
Clonidineinjection, solution100 ug/mLepiduralX Gen Pharmaceuticals, Inc.2013-10-29Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2011-08-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-25Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralClinical Solutions Wholesale2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2015-03-20Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralProficient Rx LP2009-09-21Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralBlue Point Laboratories2014-03-03Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralActavis Elizabeth LLC1995-01-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralUnit Dose Services1995-01-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMajor Pharmaceuticals2006-11-20Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralRebel Distributors Corp1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralUnit Dose Services1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMutual Pharmaceutical Company, Inc.1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralRichmond Pharmaceuticals, Inc.1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralCardinal Health2013-06-17Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralDIRECT RX2015-01-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralTYA Pharmaceuticals2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-12-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMc Kesson Contract Packaging2012-01-10Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralPreferred Pharmaceuticals, Inc2011-11-10Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralMylan Pharmaceuticals Inc.1987-06-09Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralQualitest Pharmaceuticals2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralSTAT Rx USA LLC2009-09-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralA S Medication Solutions Llc2013-06-17Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2013-06-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralCardinal Health2011-07-08Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralAmerican Health Packaging2015-10-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2015-09-17Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralbryant ranch prepack1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralAmerican Health Packaging2013-05-20Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralContract Pharmacy Services Pa2010-08-18Not applicableUs
Clonidine Hydrochlorideinjection, solution100 ug/mLintravenousWest ward Pharmaceutical Corp2011-01-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2013-02-26Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralPd Rx Pharmaceuticals, Inc.1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMed Health Pharma, LLC2011-01-10Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralPhysicians Total Care, Inc.2004-11-30Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralClinical Solutions Wholesale, Llc2009-09-21Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralREMEDYREPACK INC.2014-11-03Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralAidarex Pharmaceuticals LLC1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralREMEDYREPACK INC.2011-08-05Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralNorthwind Pharmaceuticals, LLC2014-09-24Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralDispensing Solutions, Inc.2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralClinical Solutions Wholesale2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2015-07-17Not applicableUs
Clonidine Hydrochlorideinjection, solution100 ug/mLepiduralFresenius Kabi USA, LLC2011-07-08Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralBlue Point Laboratories2014-03-03Not applicableUs
Clonidine Hydrochloridetablet, extended release.1 mg/1oralActavis Pharma, Inc.2015-06-17Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralPd Rx Pharmaceuticals, Inc.2009-09-03Not applicableUs
Clonidine Hydrochlorideinjection, solution100 ug/mLepiduralAmerican Regent, Inc.2010-04-15Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralMajor Pharmaceuticals2006-11-20Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralRebel Distributors Corp1987-09-04Not applicableUs
Clonidine Hydrochlorideinjection, solution100 ug/mLepiduralPharma Force, Inc.2009-10-16Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMylan Institutional Inc.1997-02-14Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralMutual Pharmaceutical Company, Inc.1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralRichmond Pharmaceuticals, Inc.1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralPd Rx Pharmaceuticals, Inc.2009-09-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralCarlsbad Technology, Inc2013-06-17Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralDIRECT RX2015-12-29Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMed Vantx, Inc.1995-01-03Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-12-01Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralMc Kesson Contract Packaging2011-10-03Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralbryant ranch prepack2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralPreferred Pharmaceuticals, Inc.2011-11-10Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralMylan Pharmaceuticals Inc.1987-06-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-12-16Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralNorth Star Rx Llc2013-02-04Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralLake Erie Medical DBA Quality Care Products LLC1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2013-08-28Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralCardinal Health2011-07-08Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralAmerican Health Packaging2015-10-01Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralClinical Solutions Wholesale, Llc2009-09-21Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralREMEDYREPACK INC.2015-06-16Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralAmerican Health Packaging2013-05-20Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralContract Pharmacy Services Pa2010-07-29Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralActavis Elizabeth LLC1995-01-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralAvera Mc Kennan Hospital2015-03-05Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralBlenheim Pharmacal, Inc.2011-04-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralREMEDYREPACK INC.2011-03-28Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralMed Health Pharma, LLC2011-01-10Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralQualitest Pharmaceuticals2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralApotheca, Inc1996-12-21Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralAidarex Pharmaceuticals LLC2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-05-19Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2012-08-20Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralCardinal Health2006-11-20Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralREMEDYREPACK INC.2015-07-30Not applicableUs
Clonidine Hydrochloridetablet, extended release.2 mg/1oralActavis Pharma, Inc.2015-06-17Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2016-04-11Not applicableUs
Clonidine Hydrochlorideinjection, solution500 ug/mLepiduralAmerican Regent, Inc.2010-04-15Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralMajor Pharmaceuticals2006-11-20Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralRebel Distributors Corp1987-09-04Not applicableUs
Clonidine Hydrochlorideinjection, solution500 ug/mLepiduralPharma Force, Inc.2009-10-16Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralMylan Institutional Inc.1995-06-12Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralMutual Pharmaceutical Company, Inc.1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralPhysicians Total Care, Inc.2001-10-03Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralPd Rx Pharmaceuticals, Inc.2009-09-03Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralCarlsbad Technology, Inc2013-06-17Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralDIRECT RX2015-01-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMed Vantx, Inc.2011-12-13Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-12-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralCardinal Health2009-09-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralSt Marys Medical Park Pharmacy2010-03-01Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralREMEDYREPACK INC.2015-12-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1995-01-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-13Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-12-16Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralNorth Star Rx Llc2013-02-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralREMEDYREPACK INC.2014-07-18Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralA S Medication Solutions Llc2013-02-04Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralClinical Solutions Wholesale2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2015-03-07Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralProficient Rx LP1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralBlue Point Laboratories2014-03-03Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralActavis Elizabeth LLC1995-01-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralBlenheim Pharmacal, Inc.2010-04-08Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralREMEDYREPACK INC.2011-07-29Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralMed Health Pharma, LLC2011-01-10Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralQualitest Pharmaceuticals2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralCardinal Health2011-07-08Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralAmerican Health Packaging2015-10-01Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralREMEDYREPACK INC.2015-08-31Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralbryant ranch prepack1995-01-03Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralPreferred Pharmaceuticals, Inc2011-11-10Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralMylan Pharmaceuticals Inc.1987-06-09Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralREMEDYREPACK INC.2011-04-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralPd Rx Pharmaceuticals, Inc.2009-09-03Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralMylan Institutional Inc.1995-06-12Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralPhysicians Total Care, Inc.1995-01-09Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralCarlsbad Technology, Inc2013-06-17Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralAmerican Health Packaging2013-05-20Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralDispensing Solutions, Inc.2007-03-09Not applicableUs
Clonidine Hydrochlorideinjection, solution500 ug/mLintravenousWest ward Pharmaceutical Corp2011-01-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralRichmond Pharmaceuticals, Inc.1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralCardinal Health2009-09-03Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralDIRECT RX2014-01-01Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralTYA Pharmaceuticals1987-09-04Not applicableUs
Clonidine Hydrochloridetablet.1 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-22Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-12-16Not applicableUs
Clonidine Hydrochloridetablet.3 mg/1oralNorth Star Rx Llc2013-02-04Not applicableUs
Clonidine Hydrochloridetablet.2 mg/1oralUnit Dose Services2007-03-09Not applicableUs
Clonidine Hydrochloride Extended-releasetablet, extended release.2 mg/1oralPar Pharmaceutical2013-09-30Not applicableUs
Clonidine Hydrochloride Extended-releasetablet, extended release.1 mg/1oralGolden State Medical Supply, Inc.2015-09-30Not applicableUs
Clonidine Hydrochloride Extended-releasetablet, extended release.1 mg/1oralAmerican Health Packaging2014-10-27Not applicableUs
Clonidine Hydrochloride Extended-releasetablet, extended release.1 mg/1oralPar Pharmaceutical2013-09-30Not applicableUs
Clonidine Transdermal Systempatch.2 mg/dtransdermalActavis Pharma, Inc.2014-05-06Not applicableUs
Clonidine Transdermal Systempatch.3 mg/dtransdermalActavis Pharma, Inc.2014-05-06Not applicableUs
Clonidine Transdermal Systempatch.1 mg/dtransdermalActavis Pharma, Inc.2014-05-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Catapres-TTSBoehringer Ingelheim
CatapresanBoehringer Ingelheim
CatapressanBoehringer Ingelheim
DixaritBoehringer Ingelheim
IsoglauconAgepha
Run RuiBausch & Lomb
VelarilRoemmers
WinpressWinston
Brand mixtures
NameLabellerIngredients
ClorpresMylan Pharmaceuticals Inc.
Combipres 0.1/15 TabBoehringer Ingelheim (Canada) Ltd Ltee
Salts
Name/CASStructureProperties
Clonidine Hydrochloride
4205-91-8
Thumb
  • InChI Key: ZNIFSRGNXRYGHF-UHFFFAOYSA-N
  • Monoisotopic Mass: 264.994030456
  • Average Mass: 266.555
DBSALT000538
Categories
UNIIMN3L5RMN02
CAS number4205-90-7
WeightAverage: 230.094
Monoisotopic: 229.017352717
Chemical FormulaC9H9Cl2N3
InChI KeyInChIKey=GJSURZIOUXUGAL-UHFFFAOYSA-N
InChI
InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
IUPAC Name
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
SMILES
ClC1=CC=CC(Cl)=C1NC1=NCCN1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassHalobenzenes
Direct ParentDichlorobenzenes
Alternative Parents
Substituents
  • 1,3-dichlorobenzene
  • Aryl halide
  • Aryl chloride
  • 2-imidazoline
  • Guanidine
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationMay be used as an adjunct in the treatment of hypertension, as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone, for differential diagnosis of pheochromocytoma in hypertensive patients, prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD).
PharmacodynamicsClonidine is an α-adrenergic agent that acts specifically on α2-receptors. α2-receptors regulate a number of signaling pathways mediated by multiple Gi proteins, Gαi1, Gαi2, and G&alphai3. Stimulation of α2-receptors mediates effects such as inhibition of adenylyl cyclase, stimulation fo phospholipase D, stimulation of mitogen-activated protein kinases, stimulation of K+ currents and inhibition of Ca2+ currents. Three G-protein coupled α2-receptor subtypes have been identified: α2A, α2B, and α2C. Each subtype has a unique pattern of tissue distribution in the central nervous system and peripheral tissues. The α2A-receptor is widely distributed throughout the central nervous system; it is found in the locus coeruleus, brain stem nuclei, cerebral cortex, septum, hypothalamus, and hippocampus. α2A-receptors are also expressed in the kidneys, spleen, thymus, lung and salivary glands. The α2C-receptor is primarily expressed in the central nervous system, including the striatum, olfactory tubercle, hippocampus and cerebral cortex. Low levels of the α2C-subtype are also found in the kidneys. The α2B-receptor is located primarily in the periphery (kidney, liver, lung and heart) with low levels of expression in the thalamic nuclei of the central nervous system. The α2A- and α2C-receptors are located presynaptically and inhibit the released of noradrenaline from sympathetic nerves. Stimulation of these receptors decreases sympathetic tone, resulting in decreases in blood pressure and heart rate. Sedation and analgesia is mediated by centrally located α2A-receptors, while peripheral α2B-receptors mediate constriction of vascular smooth muscle. α2A-Receptors also mediate essential components of the analgesic effect of nitrous oxide in the spinal cord. Clonidine stimulates all three α2-receptor subtypes with similar potency. Its actions in the nervous system decreases blood pressure in patients with hypertension and decreases sympathetic overactivity in patients undergoing opioid withdrawal. Clonidine is also a potent sedative and analgesic and can prevent post-operative shivering in intensive and post-operative care. Its use in differential diagnosis of pheochromocytoma owes to the fact that hypertension in patients with pheochromocytoma is refractory to antihypertensive treatment with clonidine.
Mechanism of actionSee Pharmacology section above.
Related Articles
AbsorptionWell absorbed following oral administration. Bioavailability following chronic administration is approximately 65%.
Volume of distributionNot Available
Protein binding20-40%, primarily to albumin
Metabolism

Hepatic. Metabolized via minor pathways. The major metabolite, p-hydroxyclonidine, is present in concentrations less than 10% of those of unchanged clonidine in urine. Four metabolites have been detected, but only p-hydroxyclonidine has been identified.

SubstrateEnzymesProduct
Clonidine
4-HydroxyclonidineDetails
Route of eliminationNot Available
Half life6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by p-hydroxyclonidine.
ClearanceNot Available
ToxicityOral LD50 is 150 mg/kg in rat and 30 mg/kg in dog. Symptoms of overdose include constriction of pupils of the eye, drowsiness, high blood pressure followed by a drop in pressure, irritability, low body temperature, slowed breathing, slowed heartbeat, slowed reflexes, and weakness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9632
Blood Brain Barrier+0.9402
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6305
P-glycoprotein inhibitor INon-inhibitor0.9061
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.745
CYP450 2C9 substrateNon-substrate0.8219
CYP450 2D6 substrateNon-substrate0.6984
CYP450 3A4 substrateNon-substrate0.6353
CYP450 1A2 substrateNon-inhibitor0.8998
CYP450 2C9 inhibitorNon-inhibitor0.7681
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.8732
CYP450 3A4 inhibitorNon-inhibitor0.8332
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.803
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9303
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity3.5030 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7232
hERG inhibition (predictor II)Non-inhibitor0.8905
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim
  • Aveva drug delivery systems inc
  • Mylan technologies inc
  • Tris pharma inc
  • Pharmaforce inc
  • Bioniche pharma usa llc
  • Actavis elizabeth llc
  • American therapeutics inc
  • Dava pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Impax laboratories inc
  • Interpharm inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Unichem laboratories ltd
  • Vintage pharmaceuticals llc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Shionogi pharma inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral.1 mg
Tabletoral.2 mg
Patchtransdermal.1 mg/d
Patchtransdermal.2 mg/d
Patchtransdermal.3 mg/d
Patch, extended releasetransdermal.1 mg/24h
Patch, extended releasetransdermal.2 mg/24h
Patch, extended releasetransdermal.3 mg/24h
Injection, solutionepidural100 ug/mL
Injection, solutionepidural500 ug/mL
Injection, solutionintravenous100 ug/mL
Injection, solutionintravenous500 ug/mL
Tabletoral.1 mg/1
Tabletoral.2 mg/1
Tabletoral.3 mg/1
Tablet, extended releaseoral.1 mg/1
Tablet, extended releaseoral.2 mg/1
Tabletoral
Tabletoral0.025 mg
Injection, solutionepidural.1 mg/mL
Injection, solutionepidural.5 mg/mL
Tablet, extended releaseoral.17 mg/1
For suspension, extended releaseoral.09 mg/mL
Tablet, extended releaseoral.26 mg/1
Tabletoral0.1 mg
Tabletoral0.2 mg
Prices
Unit descriptionCostUnit
Catapres-TTS-3 4 0.3 mg/24hr Patches Box328.42USD box
CloNIDine HCl 4 0.3 mg/24hr Patches Box279.9USD box
Catapres-TTS-2 4 0.2 mg/24hr Patches Box236.75USD box
CloNIDine HCl 4 0.2 mg/24hr Patches Box201.75USD box
Catapres-TTS-1 4 0.1 mg/24hr Patches Box141.08USD box
CloNIDine HCl 4 0.1 mg/24hr Patches Box119.84USD box
Catapres-tts 3 patch78.95USD patch
Clonidine 0.3 mg/day patch67.28USD patch
Clonidine hcl powder53.09USD g
Clonidine 0.2 mg/day patch48.5USD patch
Duraclon 500 mcg/ml vial47.4USD ml
Catapres-tts 2 patch39.23USD patch
Clonidine 0.1 mg/day patch28.81USD patch
Catapres-tts 1 patch21.18USD patch
Clonidine 5000 mcg/10 ml vial21.0USD ml
Duraclon 0.1 mg/ml vial14.4USD ml
Clonidine 1000 mcg/10 ml vial5.04USD ml
Catapres 0.3 mg tablet2.98USD tablet
Catapres 0.2 mg tablet2.35USD tablet
Catapres 0.1 mg tablet1.57USD tablet
Clonidine hcl 0.3 mg tablet0.5USD tablet
Clonidine hcl 0.2 mg tablet0.35USD tablet
Catapres 0.2 mg Tablet0.35USD tablet
Apo-Clonidine 0.2 mg Tablet0.33USD tablet
Novo-Clonidine 0.2 mg Tablet0.33USD tablet
Nu-Clonidine 0.2 mg Tablet0.33USD tablet
Dixarit 0.025 mg Tablet0.28USD tablet
Clonidine hcl 0.1 mg tablet0.24USD tablet
Catapres 0.1 mg Tablet0.19USD tablet
Apo-Clonidine 0.1 mg Tablet0.18USD tablet
Novo-Clonidine 0.1 mg Tablet0.18USD tablet
Nu-Clonidine 0.1 mg Tablet0.18USD tablet
Apo-Clonidine 0.025 mg Tablet0.16USD tablet
Novo-Clonidine 0.025 mg Tablet0.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5869100 No1993-10-132013-10-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point3053,202,660
water solubilityAppreciableNot Available
logP1.59HANSCH,C & LEO,AJ (1985)
Caco2 permeability-4.59ADME Research, USCD
pKa8.05 (at 25 °C)KONTTURI,K & MURTOMAKI,L (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.48 mg/mLALOGPS
logP2.55ALOGPS
logP2.49ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area36.42 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity59.09 m3·mol-1ChemAxon
Polarizability21.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-003r-5970000000-33c27878b8b7ad9d5d75View in MoNA
References
Synthesis Reference

David R. Pierce, William D. Dean, Michael E. Deason, “Process for preparation of clonidine derivatives.” U.S. Patent US5684156, issued October, 1968.

US5684156
General References
  1. Schapiro NA: "Dude, you don't have Tourette's:" Tourette's syndrome, beyond the tics. Pediatr Nurs. 2002 May-Jun;28(3):243-6, 249-53. [PubMed:12087644 ]
  2. Hossmann V, Maling TJ, Hamilton CA, Reid JL, Dollery CT: Sedative and cardiovascular effects of clonidine and nitrazepam. Clin Pharmacol Ther. 1980 Aug;28(2):167-76. [PubMed:7398184 ]
External Links
ATC CodesC02LC51C02AC01C02LC01N02CX02S01EA04
AHFS Codes
  • 24:08.16
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clonidine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Clonidine.
AbirateroneThe serum concentration of Clonidine can be increased when it is combined with Abiraterone.
AcebutololClonidine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clonidine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clonidine.
AcetaminophenThe serum concentration of Clonidine can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Acetazolamide.
AcetyldigitoxinClonidine may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Clonidine.
AfatinibThe serum concentration of Clonidine can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clonidine.
AlbendazoleThe serum concentration of Clonidine can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.
AldosteroneThe serum concentration of Clonidine can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Clonidine can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clonidine.
AlfentanilThe serum concentration of Clonidine can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Clonidine is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Clonidine.
AliskirenClonidine may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Clonidine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clonidine.
AlprenololClonidine may increase the hypotensive activities of Alprenolol.
AmantadineThe serum concentration of Clonidine can be increased when it is combined with Amantadine.
AmbrisentanClonidine may increase the hypotensive activities of Ambrisentan.
AmifostineClonidine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Clonidine is combined with Amiloride.
AmineptineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Amineptine.
Aminohippuric acidThe serum concentration of Clonidine can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Clonidine can be decreased when it is combined with Amiodarone.
AmiodaroneClonidine may increase the bradycardic activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonidine.
AmitriptylineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Clonidine is combined with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Clonidine.
AmobarbitalAmobarbital may increase the hypotensive activities of Clonidine.
AmobarbitalThe risk or severity of adverse effects can be increased when Clonidine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Clonidine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clonidine.
AmprenavirThe serum concentration of Clonidine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Clonidine can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Clonidine is combined with Amyl Nitrite.
ApraclonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Apraclonidine.
AprepitantThe serum concentration of Clonidine can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the hypotensive activities of Clonidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Clonidine is combined with Aripiprazole.
ArotinololClonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
ArtemetherThe metabolism of Clonidine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Clonidine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clonidine.
AstemizoleThe serum concentration of Clonidine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Clonidine can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Clonidine.
AtomoxetineThe metabolism of Clonidine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Clonidine can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clonidine.
AzelastineClonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Clonidine can be increased when it is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clonidine is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Clonidine can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clonidine.
BarbitalBarbital may increase the hypotensive activities of Clonidine.
BarbitalThe risk or severity of adverse effects can be increased when Clonidine is combined with Barbital.
BefunololClonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilBenazepril may increase the hypotensive activities of Clonidine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Clonidine.
BenmoxinBenmoxin may increase the hypotensive activities of Clonidine.
BenzocaineThe serum concentration of Clonidine can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Clonidine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clonidine.
BepridilClonidine may increase the hypotensive activities of Bepridil.
BeractantClonidine may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Clonidine.
BethanidineBethanidine may increase the hypotensive activities of Clonidine.
BevantololClonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BexaroteneThe serum concentration of Clonidine can be decreased when it is combined with Bexarotene.
BimatoprostClonidine may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Clonidine can be increased when it is combined with Biperiden.
BisoprololClonidine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Clonidine can be decreased when combined with Boceprevir.
BopindololClonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibThe metabolism of Clonidine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Clonidine can be decreased when it is combined with Bosentan.
BosentanClonidine may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Clonidine can be increased when it is combined with Bosutinib.
BretyliumBretylium may increase the bradycardic activities of Clonidine.
BretyliumClonidine may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clonidine is combined with Brexpiprazole.
BrimonidineClonidine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Clonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonidine.
BromocriptineThe serum concentration of Clonidine can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clonidine.
BufuralolClonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BumetanideThe risk or severity of adverse effects can be increased when Clonidine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clonidine.
BupranololClonidine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Clonidine can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Clonidine is combined with Buprenorphine.
BupropionThe metabolism of Clonidine can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Clonidine can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Clonidine is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clonidine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Clonidine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clonidine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Clonidine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clonidine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clonidine.
CabazitaxelThe serum concentration of Clonidine can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Clonidine can be increased when it is combined with Caffeine.
CalfactantClonidine may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.
CandesartanClonidine may increase the hypotensive activities of Candesartan.
CandoxatrilClonidine may increase the hypotensive activities of Candoxatril.
CaptoprilClonidine may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Clonidine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Clonidine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonidine.
CaroxazoneCaroxazone may increase the hypotensive activities of Clonidine.
CarteololCarteolol may increase the hypotensive activities of Clonidine.
CarvedilolClonidine may increase the hypotensive activities of Carvedilol.
CaspofunginThe serum concentration of Clonidine can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Clonidine can be decreased when combined with Celecoxib.
CeliprololClonidine may increase the hypotensive activities of Celiprolol.
CeritinibClonidine may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Clonidine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clonidine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clonidine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clonidine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clonidine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clonidine.
ChloroquineThe serum concentration of Clonidine can be increased when it is combined with Chloroquine.
ChlorothiazideClonidine may increase the hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Clonidine can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Clonidine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Clonidine can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Clonidine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clonidine.
CholecalciferolThe metabolism of Clonidine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Clonidine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Clonidine can be decreased when it is combined with Cholic Acid.
CilazaprilClonidine may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Clonidine can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Clonidine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clonidine.
CiprofloxacinThe serum concentration of Clonidine can be increased when it is combined with Ciprofloxacin.
CitalopramThe risk or severity of adverse effects can be increased when Clonidine is combined with Citalopram.
CitalopramThe serum concentration of Clonidine can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clonidine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Clonidine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Clonidine is combined with Clidinium.
ClobazamThe metabolism of Clonidine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Clonidine is combined with Clobazam.
ClofazimineThe serum concentration of Clonidine can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clonidine.
ClomipramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clomipramine.
ClomipramineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonidine is combined with Clonazepam.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonidine.
ClotrimazoleThe metabolism of Clonidine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clonidine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clozapine.
CobicistatThe serum concentration of Clonidine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clonidine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clonidine.
ColchicineThe serum concentration of Clonidine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Clonidine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Clonidine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Clonidine can be decreased when combined with Crizotinib.
CrizotinibClonidine may increase the bradycardic activities of Crizotinib.
CryptenamineClonidine may increase the hypotensive activities of Cryptenamine.
CyclizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cyclizine.
CyclobenzaprineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cyclobenzaprine.
CyclophosphamideThe serum concentration of Clonidine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Clonidine can be decreased when combined with Cyclosporine.
CyclothiazideClonidine may increase the hypotensive activities of Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clonidine.
Cyproterone acetateThe serum concentration of Clonidine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Clonidine can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Clonidine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Clonidine can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Clonidine is combined with Dantrolene.
DapagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonidine.
DapoxetineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapoxetine.
DarifenacinThe metabolism of Clonidine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Clonidine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Clonidine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Clonidine can be decreased when it is combined with Daunorubicin.
DebrisoquinClonidine may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Clonidine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Clonidine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Clonidine.
DeserpidineClonidine may increase the hypotensive activities of Deserpidine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clonidine.
DesipramineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Desipramine.
DeslanosideClonidine may increase the atrioventricular blocking (AV block) activities of Deslanoside.
DesloratadineThe serum concentration of Clonidine can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Clonidine is combined with Desloratadine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Clonidine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clonidine.
DexamethasoneThe serum concentration of Clonidine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dexmedetomidine.
DextromethorphanThe serum concentration of Clonidine can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clonidine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clonidine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Clonidine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clonidine.
DiazoxideDiazoxide may increase the hypotensive activities of Clonidine.
DiclofenacThe serum concentration of Clonidine can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Diclofenamide.
DifenoxinThe risk or severity of adverse effects can be increased when Clonidine is combined with Difenoxin.
DigitoxinClonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin.
DigoxinClonidine may increase the atrioventricular blocking (AV block) activities of Digoxin.
DigoxinThe serum concentration of Clonidine can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonidine.
DihydroergotamineThe metabolism of Clonidine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clonidine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonidine.
DiltiazemDiltiazem may increase the hypotensive activities of Clonidine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Clonidine is combined with Dimenhydrinate.
DinutuximabThe risk or severity of adverse effects can be increased when Clonidine is combined with Dinutuximab.
DiphenhydramineThe metabolism of Clonidine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clonidine.
DipyridamoleThe risk or severity of adverse effects can be increased when Clonidine is combined with Dipyridamole.
DonepezilClonidine may increase the bradycardic activities of Donepezil.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clonidine.
DorzolamideClonidine may increase the hypotensive activities of Dorzolamide.
DosulepinThe therapeutic efficacy of Clonidine can be decreased when used in combination with Dosulepin.
DoxazosinClonidine may increase the hypotensive activities of Doxazosin.
DoxepinThe therapeutic efficacy of Clonidine can be decreased when used in combination with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Clonidine is combined with Doxepin.
DoxorubicinThe serum concentration of Clonidine can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Clonidine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
DoxylamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Clonidine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
DronedaroneThe metabolism of Clonidine can be decreased when combined with Dronedarone.
DronedaroneClonidine may increase the bradycardic activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Clonidine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clonidine.
DuloxetineClonidine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Clonidine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonidine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Clonidine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Clonidine.
EfavirenzThe serum concentration of Clonidine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Clonidine is combined with Efavirenz.
EfonidipineClonidine may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Clonidine can be increased when it is combined with Elbasvir.
EliglustatThe metabolism of Clonidine can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.
EnalaprilClonidine may increase the hypotensive activities of Enalapril.
EnalaprilatClonidine may increase the hypotensive activities of Enalaprilat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clonidine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clonidine.
EnzalutamideThe serum concentration of Clonidine can be increased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Eplerenone.
EpoprostenolClonidine may increase the hypotensive activities of Epoprostenol.
EprosartanClonidine may increase the hypotensive activities of Eprosartan.
ErgonovineThe serum concentration of Clonidine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Clonidine can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Clonidine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Clonidine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Esmirtazapine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Clonidine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clonidine.
EstramustineThe serum concentration of Clonidine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Clonidine can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Clonidine can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clonidine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid.
EthanolClonidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Clonidine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonidine.
EthosuximideThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonidine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clonidine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clonidine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Clonidine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clonidine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clonidine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonidine.
EtoperidoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Etoperidone.
EtoposideThe serum concentration of Clonidine can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clonidine.
EtravirineThe serum concentration of Clonidine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Clonidine is combined with Felbamate.
FelodipineClonidine may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clonidine.
FenfluramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fenfluramine.
FenoldopamClonidine may increase the hypotensive activities of Fenoldopam.
FentanylThe serum concentration of Clonidine can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Clonidine is combined with Fentanyl.
FexofenadineThe serum concentration of Clonidine can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fexofenadine.
FidaxomicinThe serum concentration of Clonidine can be increased when it is combined with Fidaxomicin.
FingolimodClonidine may increase the bradycardic activities of Fingolimod.
FlibanserinThe risk or severity of adverse effects can be increased when Clonidine is combined with Flibanserin.
FluconazoleThe metabolism of Clonidine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clonidine.
FlunarizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clonidine.
FluoxetineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluoxetine.
FluoxetineThe serum concentration of Clonidine can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Clonidine can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Clonidine is combined with Flupentixol.
FluphenazineThe serum concentration of Clonidine can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluphenazine.
FlurazepamThe serum concentration of Clonidine can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Clonidine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clonidine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Clonidine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Clonidine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Clonidine can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Clonidine.
FosphenytoinThe risk or severity of adverse effects can be increased when Clonidine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clonidine.
FurazolidoneFurazolidone may increase the hypotensive activities of Clonidine.
FurosemideThe risk or severity of adverse effects can be increased when Clonidine is combined with Furosemide.
Fusidic AcidThe serum concentration of Clonidine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clonidine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Clonidine is combined with gabapentin enacarbil.
GalantamineClonidine may increase the bradycardic activities of Galantamine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clonidine.
GefitinibThe serum concentration of Clonidine can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Clonidine can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clonidine.
GlyburideThe serum concentration of Clonidine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Clonidine can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Clonidine can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Clonidine can be increased when it is combined with Grepafloxacin.
GuanabenzClonidine may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Clonidine.
GuanethidineClonidine may increase the hypotensive activities of Guanethidine.
GuanfacineClonidine may increase the hypotensive activities of Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clonidine.
HaloperidolThe serum concentration of Clonidine can be increased when it is combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Clonidine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clonidine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Clonidine.
HexamethoniumClonidine may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Clonidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Clonidine is combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Clonidine.
HydralazineClonidine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideClonidine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clonidine.
HydrocortisoneThe serum concentration of Clonidine can be increased when it is combined with Hydrocortisone.
HydroflumethiazideClonidine may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonidine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
HydroxyzineThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Clonidine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Iloperidone.
IloprostIloprost may increase the hypotensive activities of Clonidine.
ImatinibThe metabolism of Clonidine can be decreased when combined with Imatinib.
ImipramineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Clonidine is combined with Indalpine.
IndapamideClonidine may increase the hypotensive activities of Indapamide.
IndenololClonidine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Clonidine can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Clonidine can be increased when it is combined with Indomethacin.
IndoraminClonidine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Clonidine.
IproniazidIproniazid may increase the hypotensive activities of Clonidine.
IrbesartanClonidine may increase the hypotensive activities of Irbesartan.
IsavuconazoniumThe metabolism of Clonidine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Clonidine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clonidine.
IsoniazidThe metabolism of Clonidine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Clonidine is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Clonidine.
ItraconazoleThe serum concentration of Clonidine can be increased when it is combined with Itraconazole.
IvabradineClonidine may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Clonidine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Clonidine can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Clonidine can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clonidine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clonidine.
KetoconazoleThe serum concentration of Clonidine can be increased when it is combined with Ketoconazole.
LabetalolClonidine may increase the hypotensive activities of Labetalol.
LacidipineClonidine may increase the hypotensive activities of Lacidipine.
LacosamideClonidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonidine.
LanreotideClonidine may increase the bradycardic activities of Lanreotide.
LansoprazoleThe serum concentration of Clonidine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Clonidine can be increased when it is combined with Lapatinib.
LatanoprostClonidine may increase the hypotensive activities of Latanoprost.
LercanidipineLercanidipine may increase the hypotensive activities of Clonidine.
LevetiracetamThe risk or severity of adverse effects can be increased when Clonidine is combined with Levetiracetam.
LevobunololThe risk or severity of adverse effects can be increased when Clonidine is combined with Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clonidine.
LevocabastineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levocetirizine.
LevodopaClonidine may increase the orthostatic hypotensive activities of Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Clonidine.
LevofloxacinThe serum concentration of Clonidine can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clonidine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Clonidine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Clonidine.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clonidine.
LevothyroxineThe serum concentration of Clonidine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Clonidine can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Clonidine is combined with Lidocaine.
LiothyronineThe serum concentration of Clonidine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Clonidine can be decreased when it is combined with Liotrix.
LisinoprilClonidine may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Clonidine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Clonidine.
LofexidineClonidine may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Clonidine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Clonidine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Clonidine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Clonidine can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Clonidine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clonidine.
LorcaserinThe metabolism of Clonidine can be decreased when combined with Lorcaserin.
LosartanClonidine may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Clonidine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clonidine.
Lu AA21004The risk or severity of adverse effects can be increased when Clonidine is combined with Lu AA21004.
LucinactantClonidine may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Clonidine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Clonidine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Clonidine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine.
MacitentanClonidine may increase the hypotensive activities of Macitentan.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clonidine is combined with Magnesium Sulfate.
ManidipineClonidine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Clonidine is combined with Mannitol.
MaprotilineThe serum concentration of Clonidine can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Clonidine is combined with Maprotiline.
MebanazineMebanazine may increase the hypotensive activities of Clonidine.
MebendazoleThe serum concentration of Clonidine can be increased when it is combined with Mebendazole.
MecamylamineClonidine may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clonidine.
MefloquineThe serum concentration of Clonidine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Clonidine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clonidine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clonidine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonidine.
MeprobamateThe serum concentration of Clonidine can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Clonidine is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonidine.
MetaxaloneThe risk or severity of adverse effects can be increased when Clonidine is combined with Metaxalone.
MethadoneThe serum concentration of Clonidine can be increased when it is combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Clonidine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clonidine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clonidine.
MethazolamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonidine.
MethohexitalMethohexital may increase the hypotensive activities of Clonidine.
MethohexitalThe risk or severity of adverse effects can be increased when Clonidine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clonidine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clonidine.
MethsuximideThe risk or severity of adverse effects can be increased when Clonidine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clonidine.
MethyldopaClonidine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Clonidine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Clonidine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Clonidine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Clonidine is combined with Methylphenobarbital.
MetipranololClonidine may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Clonidine.
MetoprololMetoprolol may increase the hypotensive activities of Clonidine.
MetyrosineClonidine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Clonidine can be decreased when combined with Mexiletine.
MianserinThe therapeutic efficacy of Clonidine can be decreased when used in combination with Mianserin.
MibefradilClonidine may increase the hypotensive activities of Mibefradil.
MiconazoleThe serum concentration of Clonidine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Clonidine can be decreased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Clonidine is combined with Midazolam.
MifepristoneThe metabolism of Clonidine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Clonidine is combined with Milnacipran.
MilnacipranMilnacipran may decrease the antihypertensive activities of Clonidine.
MinaprineMinaprine may increase the hypotensive activities of Clonidine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
MinoxidilMinoxidil may increase the hypotensive activities of Clonidine.
MirabegronThe metabolism of Clonidine can be decreased when combined with Mirabegron.
MirtazapineClonidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Mirtazapine.
MitomycinThe serum concentration of Clonidine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Clonidine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Clonidine can be decreased when it is combined with Mitoxantrone.
MoclobemideMoclobemide may increase the hypotensive activities of Clonidine.
ModafinilThe serum concentration of Clonidine can be decreased when it is combined with Modafinil.
MoexiprilClonidine may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clonidine.
MolsidomineMolsidomine may increase the hypotensive activities of Clonidine.
MorphineThe serum concentration of Clonidine can be increased when it is combined with Morphine.
MorphineThe risk or severity of adverse effects can be increased when Clonidine is combined with Morphine.
MoxonidineClonidine may increase the hypotensive activities of Moxonidine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
NabiloneThe risk or severity of adverse effects can be increased when Clonidine is combined with Nabilone.
NadololClonidine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Clonidine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clonidine.
NaltrexoneThe serum concentration of Clonidine can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Clonidine can be increased when it is combined with Naringenin.
NebivololClonidine may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Clonidine can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Clonidine can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Clonidine can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Clonidine is combined with Nesiritide.
NetupitantThe serum concentration of Clonidine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Clonidine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Clonidine.
NicardipineClonidine may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Clonidine.
NifedipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nifedipine.
NiguldipineClonidine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Clonidine can be decreased when combined with Nilotinib.
NilvadipineClonidine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Clonidine.
NisoldipineNisoldipine may increase the hypotensive activities of Clonidine.
NitrazepamThe serum concentration of Clonidine can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Clonidine is combined with Nitrazepam.
NitrendipineClonidine may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Clonidine is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Clonidine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clonidine.
NorethisteroneThe serum concentration of Clonidine can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Clonidine.
NortriptylineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nortriptyline.
ObinutuzumabClonidine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Clonidine.
OctreotideOctreotide may increase the bradycardic activities of Clonidine.
OlanzapineThe risk or severity of adverse effects can be increased when Clonidine is combined with Olanzapine.
OlaparibThe metabolism of Clonidine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Clonidine.
OlopatadineThe risk or severity of adverse effects can be increased when Clonidine is combined with Olopatadine.
OmapatrilatClonidine may increase the hypotensive activities of Omapatrilat.
OmeprazoleThe serum concentration of Clonidine can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clonidine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Clonidine.
OrphenadrineClonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clonidine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clonidine.
OsimertinibThe serum concentration of Clonidine can be increased when it is combined with Osimertinib.
OuabainClonidine may increase the atrioventricular blocking (AV block) activities of Ouabain.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clonidine.
OxprenololClonidine may increase the hypotensive activities of Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clonidine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonidine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clonidine.
P-NitrophenolThe serum concentration of Clonidine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Clonidine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Clonidine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonidine.
Palmitic AcidThe serum concentration of Clonidine can be increased when it is combined with Palmitic Acid.
PanobinostatThe metabolism of Clonidine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Clonidine can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Clonidine is combined with Papaverine.
ParaldehydeClonidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Clonidine.
PargylineClonidine may increase the hypotensive activities of Pargyline.
ParoxetineThe risk or severity of adverse effects can be increased when Clonidine is combined with Paroxetine.
ParoxetineThe serum concentration of Clonidine can be increased when it is combined with Paroxetine.
PasireotideClonidine may increase the bradycardic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Clonidine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololClonidine may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Clonidine.
PentobarbitalThe risk or severity of adverse effects can be increased when Clonidine is combined with Pentobarbital.
PentoliniumClonidine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Clonidine.
PerampanelThe risk or severity of adverse effects can be increased when Clonidine is combined with Perampanel.
PerindoprilClonidine may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clonidine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clonidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clonidine.
PhenelzinePhenelzine may increase the hypotensive activities of Clonidine.
PheniprazinePheniprazine may increase the hypotensive activities of Clonidine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Clonidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Clonidine is combined with Phenobarbital.
PhenoxybenzamineClonidine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Clonidine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Clonidine.
PhentolamineClonidine may increase the hypotensive activities of Phentolamine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clonidine.
PimozideThe serum concentration of Clonidine can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Clonidine is combined with Pimozide.
PinacidilClonidine may increase the hypotensive activities of Pinacidil.
PindololClonidine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clonidine.
PipotiazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pipotiazine.
PirlindolePirlindole may increase the hypotensive activities of Clonidine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Clonidine.
PizotifenThe risk or severity of adverse effects can be increased when Clonidine is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Clonidine can be decreased when it is combined with Platelet Activating Factor.
PolythiazideClonidine may increase the hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Clonidine is combined with Pomalidomide.
PonatinibThe serum concentration of Clonidine can be increased when it is combined with Ponatinib.
Poractant alfaClonidine may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe serum concentration of Clonidine can be increased when it is combined with Posaconazole.
PractololClonidine may increase the atrioventricular blocking (AV block) activities of Practolol.
PramipexoleClonidine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clonidine.
PravastatinThe serum concentration of Clonidine can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clonidine.
PrazosinPrazosin may increase the hypotensive activities of Clonidine.
PrednisoneThe serum concentration of Clonidine can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clonidine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Clonidine.
PrimidonePrimidone may increase the hypotensive activities of Clonidine.
PrimidoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Primidone.
ProbenecidThe serum concentration of Clonidine can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clonidine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonidine.
ProgesteroneThe serum concentration of Clonidine can be decreased when it is combined with Progesterone.
PromazineThe metabolism of Clonidine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Promazine.
PromethazineThe serum concentration of Clonidine can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Promethazine.
PropafenoneThe serum concentration of Clonidine can be increased when it is combined with Propafenone.
PropafenoneClonidine may increase the bradycardic activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clonidine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clonidine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Clonidine.
PropranololPropranolol may increase the hypotensive activities of Clonidine.
ProtriptylineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Clonidine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Clonidine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clonidine.
QuercetinThe serum concentration of Clonidine can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quetiapine.
QuinacrineThe serum concentration of Clonidine can be increased when it is combined with Quinacrine.
QuinaprilClonidine may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Clonidine can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Clonidine.
RamelteonThe risk or severity of adverse effects can be increased when Clonidine is combined with Ramelteon.
RamiprilRamipril may increase the hypotensive activities of Clonidine.
RanitidineThe serum concentration of Clonidine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Clonidine can be increased when it is combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Clonidine.
ReboxetineThe serum concentration of Clonidine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Clonidine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonidine.
RemikirenRemikiren may increase the hypotensive activities of Clonidine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonidine.
RescinnamineClonidine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Clonidine.
RifabutinThe metabolism of Clonidine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Clonidine can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Clonidine can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Clonidine can be increased when it is combined with Rilpivirine.
RiociguatClonidine may increase the hypotensive activities of Riociguat.
RisperidoneClonidine may increase the hypotensive activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Clonidine.
RitonavirThe serum concentration of Clonidine can be decreased when it is combined with Ritonavir.
RituximabClonidine may increase the hypotensive activities of Rituximab.
RivastigmineClonidine may increase the bradycardic activities of Rivastigmine.
RolapitantThe serum concentration of Clonidine can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clonidine.
RopiniroleClonidine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Clonidine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonidine.
RotigotineClonidine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clonidine.
RuxolitinibRuxolitinib may increase the bradycardic activities of Clonidine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clonidine.
SafrazineSafrazine may increase the hypotensive activities of Clonidine.
SaprisartanClonidine may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Clonidine can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Clonidine can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Clonidine.
SecobarbitalThe risk or severity of adverse effects can be increased when Clonidine is combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Clonidine.
SelexipagClonidine may increase the hypotensive activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clonidine.
SertralineThe risk or severity of adverse effects can be increased when Clonidine is combined with Sertraline.
SertralineThe serum concentration of Clonidine can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clonidine.
SildenafilSildenafil may increase the antihypertensive activities of Clonidine.
SiltuximabThe serum concentration of Clonidine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Clonidine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Clonidine can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Clonidine can be decreased when it is combined with Sirolimus.
SitaxentanClonidine may increase the hypotensive activities of Sitaxentan.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Clonidine.
SorafenibThe serum concentration of Clonidine can be increased when it is combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Clonidine.
SpiraprilClonidine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Clonidine.
St. John's WortThe serum concentration of Clonidine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Clonidine can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Clonidine is combined with Stiripentol.
StreptozocinThe serum concentration of Clonidine can be decreased when it is combined with Streptozocin.
SufentanilClonidine may increase the bradycardic activities of Sufentanil.
SulfinpyrazoneThe serum concentration of Clonidine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Clonidine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonidine.
SumatriptanThe serum concentration of Clonidine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Clonidine can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Clonidine is combined with Suvorexant.
TacrineThe serum concentration of Clonidine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Clonidine can be decreased when it is combined with Tacrolimus.
TadalafilTadalafil may increase the antihypertensive activities of Clonidine.
TamoxifenThe serum concentration of Clonidine can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Clonidine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Clonidine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Clonidine can be increased when it is combined with Taurocholic Acid.
TelaprevirThe metabolism of Clonidine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Clonidine can be decreased when combined with Telithromycin.
TelmisartanClonidine may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clonidine.
TemocaprilClonidine may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Clonidine can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Clonidine can be decreased when combined with Tenofovir.
TerazosinThe risk or severity of adverse effects can be increased when Clonidine is combined with Terazosin.
TerbinafineThe metabolism of Clonidine can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Clonidine can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Clonidine can be decreased when it is combined with Teriflunomide.
TerlipressinClonidine may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Clonidine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Clonidine can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clonidine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clonidine.
ThalidomideClonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clonidine.
TheophyllineThe metabolism of Clonidine can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Clonidine.
ThiamylalThe risk or severity of adverse effects can be increased when Clonidine is combined with Thiamylal.
ThiopentalThiopental may increase the hypotensive activities of Clonidine.
ThiopentalThe risk or severity of adverse effects can be increased when Clonidine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clonidine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonidine.
TiagabineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tiagabine.
TianeptineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Tianeptine.
TiboloneClonidine may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Clonidine can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Clonidine can be decreased when combined with Ticlopidine.
TicrynafenClonidine may increase the hypotensive activities of Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clonidine.
TimololTimolol may increase the hypotensive activities of Clonidine.
TipranavirThe metabolism of Clonidine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tizanidine.
TocilizumabThe serum concentration of Clonidine can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Clonidine.
TolazolineClonidine may increase the hypotensive activities of Tolazoline.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonidine.
ToloxatoneToloxatone may increase the hypotensive activities of Clonidine.
TolvaptanThe serum concentration of Clonidine can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clonidine.
TorasemideTorasemide may increase the hypotensive activities of Clonidine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonidine.
TrandolaprilTrandolapril may increase the hypotensive activities of Clonidine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Clonidine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Clonidine.
TranylcypromineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tranylcypromine.
TravoprostTravoprost may increase the hypotensive activities of Clonidine.
TrazodoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Trazodone.
TrazodoneThe serum concentration of Clonidine can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Clonidine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Clonidine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clonidine.
TrichlormethiazideClonidine may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Clonidine can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Clonidine can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Triflupromazine.
TrimazosinClonidine may increase the hypotensive activities of Trimazosin.
TrimethaphanClonidine may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe serum concentration of Clonidine can be decreased when it is combined with Trimethoprim.
TrimipramineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clonidine.
TroleandomycinThe serum concentration of Clonidine can be increased when it is combined with Troleandomycin.
UdenafilUdenafil may increase the antihypertensive activities of Clonidine.
UnoprostoneClonidine may increase the hypotensive activities of Unoprostone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clonidine.
ValsartanValsartan may increase the hypotensive activities of Clonidine.
VardenafilVardenafil may increase the antihypertensive activities of Clonidine.
VemurafenibThe serum concentration of Clonidine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Clonidine can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Clonidine is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Clonidine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Vilazodone.
VinblastineThe serum concentration of Clonidine can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Clonidine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Clonidine can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Clonidine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Clonidine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clonidine.
XylometazolineClonidine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Clonidine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clonidine.
ZiconotideThe risk or severity of adverse effects can be increased when Clonidine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Zimelidine.
ZimelidineThe serum concentration of Clonidine can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Clonidine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clonidine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clonidine.
ZonisamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clonidine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clonidine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonidine.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL: alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 2002 Jan;300(1):282-90. [PubMed:11752127 ]
  2. Lavand'homme PM, Ma W, De Kock M, Eisenach JC: Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology. 2002 Oct;97(4):972-80. [PubMed:12357167 ]
  3. Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M: The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol. 2004 Aug 23;497(2):161-71. [PubMed:15306201 ]
  4. Ozdogan UK, Lahdesmaki J, Mansikka H, Scheinin M: Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur J Pharmacol. 2004 Feb 6;485(1-3):193-6. [PubMed:14757140 ]
  5. Wang XM, Zhang ZJ, Bains R, Mokha SS: Effect of antisense knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain. 2002 Jul;98(1-2):27-35. [PubMed:12098614 ]
  6. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. PDSP Ki Database [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]
  2. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  3. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
  4. Martel F, Vetter T, Russ H, Grundemann D, Azevedo I, Koepsell H, Schomig E: Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):320-6. [PubMed:8878062 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924 ]
  2. Martel F, Grundemann D, Calhau C, Schomig E: Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters. Naunyn Schmiedebergs Arch Pharmacol. 2001 Jan;363(1):40-9. [PubMed:11191835 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
  2. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23